Premium Content Regulatory alerts

Insulins (all types): risk of cutaneous amyloidosis at injection site

Drug safety update: Cutaneous amyloidosis at the injection site has been reported in patients using insulin and this may affect glycaemic control. Remind patients to rotate injection sites within the same body region.

Please sign in or register for FREE

No comments yet.